


ESMO Preceptorship Programme


Prague, April 2017

Ovarian Cancer

Cancer occurrence



Cancer mortality



Ovarian Cancer Preceptorship Course

- Small percentage of total cancers
- Specialist knowledge
- International collaboration
 - European
 - ESMO
 - ESGO
 - ENGOT
 - Global
 - ASCO
 - IGCS
 - GCIG

Faculty

- Jonathan Ledermann (UK)
- Susana Banerjee (UK)
- Nicoletta Colombo (Italy)
- Christina Fotopoulou (UK)
- Christian Marth (Austria)
- Glenn McCluggage (UK)
- Iain McNeish (UK)
- Mansoor Mirza (Denmark)
- Andrés Poveda (Spain)
- Isabelle Ray-Coquard (France)
- Cristiana Sessa (Switzerland)

Uncommon but complex!

- Not one disease- pathology and biology very different
- Multi-disciplinary – surgery and drug therapy
- Unusually responsive to chemotherapy
- Some patients presenting with advanced disease are cured!
- Often responsive to multiple lines of therapy
- Excellent test-bed for novel therapies
- Patients may live for several years after initial presentation
- Complex management of end-stage disease

ESMO Resources

Annals of Oncology 24 (Supplement 6): vi24-vi32, 2013
doi:10.1093/annonc/mdt333

eUpdate – Ovarian Cancer Treatment Recommendations

Published: 21 September 2016. Authors: J.A. Ledermann¹, C. Sessa² & N. Colombo³ on behalf of the ESMO Guidelines Committee

¹UCL Cancer Institute, University College London, London; ²Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland; ³European Institute of Oncology, University of Milan Bicocca, Milan, Italy.

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

N. Colombo^{1,5}, M. Peiretti¹, A. Garbi¹, S. Carinelli^{2,4}, C. Marini⁵ & C. Sessa^{3,4}, on behalf of the ESMO Guidelines Working Group*

Departments of ¹Gynecologic Oncology, ²Pathology, European Institute of Oncology, Milan, Italy; ³Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; ⁴Unit of New Drugs & Innovative Therapies, Department of Medical Oncology, San Raffaele Hospital, O.U. Medicine 1Q-A Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy; ⁵Department of Gynecologic Oncology, Università Milano-Bicocca, Milan, Italy

Annals of Oncology 23 (Supplement 7): vi20-vi26, 2012
doi:10.1093/annonc/mds223



[View More by This Developer](#)

Description

Developed by experts, the ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. Each CPG includes information on the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment.

[European Society for Medical Oncology – ESMO Web Site](#) [ESMO Cancer Guidelines Support](#) [...More](#)

What's New in Version 1.4

Graphical enhancements for the new iOS7



Oncology Pro

ESMO E-Learn Chemotherapy

Learning Objectives

1. To provide an update
2. To provide a summary of intraperitoneal chemotherapy
3. To provide key information on the management of ovarian cancer

Title

Ovarian Cancer IP Chemotherapy



Pierfranco
Conte
[Read more](#)

In the chemotherapy, the pivotal feature is the evidence of the impact of intraperitoneal chemotherapy.

In the management of ovarian cancer, the objective is to obtain the best possible outcome.

PARP Inhibitors: Current and Future

Date: 03 Apr 2017

Topic: Ovarian Cancer

Speaker: Thomas Helleday



Prof. Thomas Helleday's research is mainly focused on understanding the role of DNA-damage signalling in cancer. He spoke at the ESMO Symposium on Ovarian Cancer 2017, where he spoke about PARP inhibitors and what we can expect in the future.

► Discussion Points



11th
International
Symposium

**Advanced Ovarian Cancer
Optimal Therapy. Update**

Remarks and Conclusions

Andrés Poveda

Instituto Valenciano de Oncología, Valencia, Spain

- Ovarian Cancer- Pathology and Biology
 - Underpins our knowledge and drives therapeutic research
- Surgery
 - Key aspects for medical oncologists
- The importance of multidisciplinary management
 - Choosing the right therapy for the right patient at the right time
 - First-line therapy and choices
 - Complexities of managing recurrent ovarian cancer
 - Interdisciplinary interaction
- Decision-making
 - Understanding the evidence-base developed from clinical trials
 - Increasing complexity of trial design
 - Novel methods to evaluate new drugs- molecular therapeutics and immunotherapy
- Management of patient symptoms and side-effects of treatment